VIH, dislipidemias y perspectivas de su evolución
Artículo barra lateral
PDF
FLIP
Sección: Articulo de Revisión
Cómo citar
Mendieta Zerón, H., Montenegro Cárdenas, A., Vargas Hernández, J., & Hinojosa Juárez, A. (2019). VIH, dislipidemias y perspectivas de su evolución. NOVA, 17(32), 83-93. https://doi.org/10.25058/24629448.3637
Formatos de citación
Contenido principal del artículo
Autores
Hugo Mendieta Zerón
https://orcid.org/0000-0003-3492-8950
https://orcid.org/0000-0003-3492-8950
Angela Montenegro Cárdenas
https://orcid.org/0000-0002-4024-9252
https://orcid.org/0000-0002-4024-9252
Joel Alberto Vargas Hernández
https://orcid.org/0000-0001-7404-3132
https://orcid.org/0000-0001-7404-3132
Araceli Consuelo Hinojosa Juárez
Resumen
Con el advenimiento de la terapia antirretroviral (ART), la infección por el virus de inmunodeficiencia humana (VIH) se ha convertido en una enfermedad crónica con complicaciones metabólicas importantes más acentuadas que en la población general. Mientras no se tenga una vacuna que erradique las tasas de infección y no exista una cura para esta pandemia, se debe ser más incisivo en el controlar las comorbilidades, entre las que destacan las alteraciones en el perfil de lípidos pues aumentan el riesgo cardiovascular.
Detalles del artículo
Licencia
NOVA por http://www.unicolmayor.edu.co/publicaciones/index.php/nova se distribuye bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.
Así mismo, los autores mantienen sus derechos de propiedad intelectual sobre los artículos.
Referencias
1. Ahmed D, Roy D, Cassol E. Examining Relations- hips between Metabolism and Persistent Inflam- mation in HIV Patients on Antiretroviral Therapy. Mediators Inflamm. 2018 Sep 27;2018:6238978.
2. Andrade MA, Andrade HA. Alteraciones del meta- bolismo lipídico en pacientes seropositivos para VIH con tratamiento Retroviral altamente efectivo. Rev. Cuban Cardiol Circ Cardiovasc. 2010;16(1):64-73.
3. Batterham MJ, Brown D, Workman C. Modif- ying dietary fat intake can reduce serum choleste- rol in HIV-associated hypercholesterolemia. AIDS. 2003;17(9):1414-1416.
4. Castelo Elías-Calles L, González Calero TM. Dis- lipidemia y virus de inmunodeficiencia adquirida/ SIDA. Rev. cuba endocrinol. 2010;21(2):202- 222.
5. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Re- sults from the DAD study. AIDS. 2003;17(8):1179- 1193.
6. Grinspoon S, Carr A. Cardiovascular risk and body- fat abnormalities HIV-infected adults. N Engl J Med. 2005;352(1):48-62.
7. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10(1):61-70.
8. Rodríguez-Carranza SI, Aguilar-Salinas CA. Anor- malidades metabólicas en pacientes con infección por VIH. Rev Invest Clin. 2004;56(2):193-208.
9. Husain NE, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV AIDS (Auckl). 2014;7:1-10.
10. Feeney ER, Mallon PW. HIV and HAART-As- sociated Dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63.
11. Boonthos K, Puttilerpong C, Pengsuparp T, Mano- suthi W. Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. Jpn J Infect Dis. 2018;71(3):220-224.
12. Calza L, Colangeli V, Borderi M, Manfredi R, Mar- coni L, Bon I, Re MC, Viale P. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infec- ted patients with chronic kidney disease and hyper- lipidaemia. HIV Clin Trials. 2018;19(3):120-128.
13. Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, Forga MT, Ros E. Effects of eze- timibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipi- demia: a single-arm intervention trial BMC Infect Dis. 2014;14:497.
14. Waters DD, Hsue PY. Lipid Abnormalities in Per- sons Living With HIV Infection. Can J Cardiol. 2019;35(3):249-259.
15. García Gómez Y, Mendieta Alcántara MR, Men- dieta Zerón H. Eryngium heterophyllum and Amphipterygium adstringens Tea Effect on Trigly- ceride Levels: A Clinical Trial. Trad Integr Med. 2019;4(1):22-27.
16. Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018;35:58-66.
17. Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, et al. Cardiovascular risk and endothelial function in people living with HIV/ AIDS: design of the multi-site, longitudinal Endo- Africa study in the Western Cape Province of South Africa. BMC Infect Dis. 2017;17(1):41.
18. D’Agostino RB Sr, Grundy S, Sullivan LM, Wil- son P; CHD Risk Prediction Group. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.
19. Begovac J, Dragović G, Višković K1, Kušić J, Pe- rović Mihanović M, Lukas D, et al. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on anti- retroviral therapy. Croat Med J. 2015;56(1):14-23.
20. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Mon- forte AD, De Wit S, et al; DAD study group. Pre- dicting the risk of cardiovascular disease in HIVin- fected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Re- habil. 2010;17(5):491-501.
21. Hippisley-Cox J, Coupland C, Vinogradova Y, Rob- son J, Minhas R, Sheikh A, et al. Predicting car- diovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008 Jun 28;336(7659):1475-1482.
22. Pierre S, Seo G, Rivera VR, Walsh KF, Victor JJ, Charles B, Julmiste G, Dumont E, Apollon A, Cadet M, Saint-Vil A, Marcelin A, Severe P, Lee MH, Kin- gery J, Koenig S, Fitzgerald D, Pape J, McNairy ML. Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field. J Clin Hypertens (Greenwich). 2019 Aug 26. doi: 10.1111/jch.13663.
23. Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAI- LoR Study Group TAILoR (TelmisArtan and Insu- Lin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduc- tion of Insulin Resistance in HIV-positive Indivi- duals on Combination Antiretroviral Therapy. Clin Infect Dis. 2019 Jul 3. pii: ciz589. doi: 10.1093/ cid/ciz589.
24. Kumar S, Dhanwal DK. Central obesity & dysli- pidemia in HIV patients on antiretroviral therapy. Indian J Med Res. 2018;148(4):366-368.
25. Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther. 2007;4:16.
26. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystro- phy: a model of ‘systemic steatosis’Curr Opin Lipi- dol. 2004;15(1):59-67.
27. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26-39.
28. Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;26(9):532-40.
29. Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Mi- ralles C, Domingo P, Montero M, del Rio L, Font- devila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Med. 2016;17(5):340-9.
30. Rodríguez-Díaz CE, Santiago-Rodríguez EI, Jo- vet-Toledo GG, Santana-Bagur J, Ron-Suarez Y, Orengo JC, Arbelaez F, Monsanto H. Comorbi- dities in a sample of adults with HIV in Puerto Rico: an exploratory study. HIV AIDS (Auckl). 2019;11:155-164.
31. Maggi P, Santoro CR, Nofri M, Ricci E, De Genna- ro N, Bellacosa C, Schiaroli E, Orofino G, Menza- ghi B, Di Biagio A, Squillace N, Francisci D, Vichi F, Molteni C, Bonfanti P, Gaeta GB, De Socio GV. Clusterization of co-morbidities and multi-morbidi- ties among persons living with HIV: a cross-sectio- nal study. BMC Infect Dis. 2019;19(1):555.
32. Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bas- tard JP, Vigouroux C, Boccara F, Capeau J. Me- tabolic complications affecting adipose tissue, li- pid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829-840.
33. Brites C, Nogueira RS, Gosuen GC, Kalmar EMN, Leme ST, Martins RT, Oyama T, Bastos F. Getting older with HIV: increasing frequency of comorbi- dities and polypharmacy in Brazilian HIV patients. AIDS Res Hum Retroviruses. 2019 Aug 27. doi: 10.1089/AID.2019.0069. [Epub ahead of print]
34. Mendieta-Zerón H, Huerta-Coyote O. Dyslipide- mia is a persistent problem in puerperium with or without preeclampsia. Clin Exp Obstet Gynecol. 2013;40(2):229-32.
35. Delicio AM, Lajos GJ, Amaral E, Lopes F, Cavichio- lli F, Myioshi I, Milanez H. Adverse effects of anti- retroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infect Dis. 2018;18(1):485.
36. Smith C, McFarland EJ. Update on Pediatric Hu- man Immunodeficiency Virus Infection: Para- digms in Treatment and Prevention. Adv Pediatr. 2016;63(1):147-71.
37. Manafe N, Ngale A, Biquiza N, Zimba I, Majid N, Mocumbi AO. Need for active cardiovascular screening in HIV-infected children under antire- troviral therapy in Africa. Cardiovasc Diagn Ther. 2019;9(1):68-72.
38. Arrive E, Viard JP, Salanave B, Dollfus C, Ma- theron S, Reliquet V, Arezes E, Nailler L, Vigou- roux C, Warszawski J; ANRS CO19 COVERTE and ENNS study groups. Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. PLoS One. 2018;13(11):e0206745
39. de Lima LRA, Back IC, Nunes EA, Silva DAS, Pe- troski EL. Aerobic fitness and physical activity are inversely associated with body fat, dyslipidemia and inflammatory mediators in children and adolescents living with HIV. J Sports Sci. 2019;37(1):50-58.
40. Zárate Sanabria, Andrés Gabriel et al. Intervención educativa sobre virus de inmunodeficiencia humana en la comunidad habitante de calle que asiste a un centro de acogida en la ciudad de Bogotá D.C. – Colombia. Nova, [S.l.], v. 15, n. 28, p. 11 - 17, oct. 2017. ISSN 2462-9448. Disponible en:. Fecha de acceso: 17 may. 2019 doi:ht- tps://doi.org/10.22490/24629448.2072.
41. Del Amo J, Campbell C, Navarro G, Segura F, Suárez I, Teira R, et al. HIV in Spain 2017: policies for a new management of chronicity beyond viro- logical control]. Rev Esp Salud Publica. 2018 Sep 6;92. pii: e201809062.
42. Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, Wierzbicki AS. Pro-pro- tein subtilisin kexin-9 (PCSK9) inhibition in prac- tice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13032. Epub 2017 Oct 10
43. Ruscica M, Watts GF, Sirtori CR. PCSK9 in HIV infection: New opportunity or red herring? Atheros- clerosis. 2019;284:216-217
44. Nawej Tshikung O, Calmy A. [Antiretroviral treat- ments: towards simplified regimens? Rev Med Suis- se. 2018;14(588-589):102-106.
45. Hsu DC, O’Connell RJ. Progress in HIV vac- cine development. Hum Vaccin Immunother. 2017;13(5):1018-1030.
46. Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner N; NHLBI AIDS Blood Session Wor- king Group. NHLBI AIDS Blood Session Wor- king Group. Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood. 2013;122(18):3111-3115.
2. Andrade MA, Andrade HA. Alteraciones del meta- bolismo lipídico en pacientes seropositivos para VIH con tratamiento Retroviral altamente efectivo. Rev. Cuban Cardiol Circ Cardiovasc. 2010;16(1):64-73.
3. Batterham MJ, Brown D, Workman C. Modif- ying dietary fat intake can reduce serum choleste- rol in HIV-associated hypercholesterolemia. AIDS. 2003;17(9):1414-1416.
4. Castelo Elías-Calles L, González Calero TM. Dis- lipidemia y virus de inmunodeficiencia adquirida/ SIDA. Rev. cuba endocrinol. 2010;21(2):202- 222.
5. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Re- sults from the DAD study. AIDS. 2003;17(8):1179- 1193.
6. Grinspoon S, Carr A. Cardiovascular risk and body- fat abnormalities HIV-infected adults. N Engl J Med. 2005;352(1):48-62.
7. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10(1):61-70.
8. Rodríguez-Carranza SI, Aguilar-Salinas CA. Anor- malidades metabólicas en pacientes con infección por VIH. Rev Invest Clin. 2004;56(2):193-208.
9. Husain NE, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV AIDS (Auckl). 2014;7:1-10.
10. Feeney ER, Mallon PW. HIV and HAART-As- sociated Dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63.
11. Boonthos K, Puttilerpong C, Pengsuparp T, Mano- suthi W. Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. Jpn J Infect Dis. 2018;71(3):220-224.
12. Calza L, Colangeli V, Borderi M, Manfredi R, Mar- coni L, Bon I, Re MC, Viale P. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infec- ted patients with chronic kidney disease and hyper- lipidaemia. HIV Clin Trials. 2018;19(3):120-128.
13. Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, Forga MT, Ros E. Effects of eze- timibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipi- demia: a single-arm intervention trial BMC Infect Dis. 2014;14:497.
14. Waters DD, Hsue PY. Lipid Abnormalities in Per- sons Living With HIV Infection. Can J Cardiol. 2019;35(3):249-259.
15. García Gómez Y, Mendieta Alcántara MR, Men- dieta Zerón H. Eryngium heterophyllum and Amphipterygium adstringens Tea Effect on Trigly- ceride Levels: A Clinical Trial. Trad Integr Med. 2019;4(1):22-27.
16. Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018;35:58-66.
17. Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, et al. Cardiovascular risk and endothelial function in people living with HIV/ AIDS: design of the multi-site, longitudinal Endo- Africa study in the Western Cape Province of South Africa. BMC Infect Dis. 2017;17(1):41.
18. D’Agostino RB Sr, Grundy S, Sullivan LM, Wil- son P; CHD Risk Prediction Group. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.
19. Begovac J, Dragović G, Višković K1, Kušić J, Pe- rović Mihanović M, Lukas D, et al. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on anti- retroviral therapy. Croat Med J. 2015;56(1):14-23.
20. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Mon- forte AD, De Wit S, et al; DAD study group. Pre- dicting the risk of cardiovascular disease in HIVin- fected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Re- habil. 2010;17(5):491-501.
21. Hippisley-Cox J, Coupland C, Vinogradova Y, Rob- son J, Minhas R, Sheikh A, et al. Predicting car- diovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008 Jun 28;336(7659):1475-1482.
22. Pierre S, Seo G, Rivera VR, Walsh KF, Victor JJ, Charles B, Julmiste G, Dumont E, Apollon A, Cadet M, Saint-Vil A, Marcelin A, Severe P, Lee MH, Kin- gery J, Koenig S, Fitzgerald D, Pape J, McNairy ML. Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field. J Clin Hypertens (Greenwich). 2019 Aug 26. doi: 10.1111/jch.13663.
23. Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAI- LoR Study Group TAILoR (TelmisArtan and Insu- Lin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduc- tion of Insulin Resistance in HIV-positive Indivi- duals on Combination Antiretroviral Therapy. Clin Infect Dis. 2019 Jul 3. pii: ciz589. doi: 10.1093/ cid/ciz589.
24. Kumar S, Dhanwal DK. Central obesity & dysli- pidemia in HIV patients on antiretroviral therapy. Indian J Med Res. 2018;148(4):366-368.
25. Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther. 2007;4:16.
26. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystro- phy: a model of ‘systemic steatosis’Curr Opin Lipi- dol. 2004;15(1):59-67.
27. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26-39.
28. Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;26(9):532-40.
29. Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Mi- ralles C, Domingo P, Montero M, del Rio L, Font- devila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Med. 2016;17(5):340-9.
30. Rodríguez-Díaz CE, Santiago-Rodríguez EI, Jo- vet-Toledo GG, Santana-Bagur J, Ron-Suarez Y, Orengo JC, Arbelaez F, Monsanto H. Comorbi- dities in a sample of adults with HIV in Puerto Rico: an exploratory study. HIV AIDS (Auckl). 2019;11:155-164.
31. Maggi P, Santoro CR, Nofri M, Ricci E, De Genna- ro N, Bellacosa C, Schiaroli E, Orofino G, Menza- ghi B, Di Biagio A, Squillace N, Francisci D, Vichi F, Molteni C, Bonfanti P, Gaeta GB, De Socio GV. Clusterization of co-morbidities and multi-morbidi- ties among persons living with HIV: a cross-sectio- nal study. BMC Infect Dis. 2019;19(1):555.
32. Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bas- tard JP, Vigouroux C, Boccara F, Capeau J. Me- tabolic complications affecting adipose tissue, li- pid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829-840.
33. Brites C, Nogueira RS, Gosuen GC, Kalmar EMN, Leme ST, Martins RT, Oyama T, Bastos F. Getting older with HIV: increasing frequency of comorbi- dities and polypharmacy in Brazilian HIV patients. AIDS Res Hum Retroviruses. 2019 Aug 27. doi: 10.1089/AID.2019.0069. [Epub ahead of print]
34. Mendieta-Zerón H, Huerta-Coyote O. Dyslipide- mia is a persistent problem in puerperium with or without preeclampsia. Clin Exp Obstet Gynecol. 2013;40(2):229-32.
35. Delicio AM, Lajos GJ, Amaral E, Lopes F, Cavichio- lli F, Myioshi I, Milanez H. Adverse effects of anti- retroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infect Dis. 2018;18(1):485.
36. Smith C, McFarland EJ. Update on Pediatric Hu- man Immunodeficiency Virus Infection: Para- digms in Treatment and Prevention. Adv Pediatr. 2016;63(1):147-71.
37. Manafe N, Ngale A, Biquiza N, Zimba I, Majid N, Mocumbi AO. Need for active cardiovascular screening in HIV-infected children under antire- troviral therapy in Africa. Cardiovasc Diagn Ther. 2019;9(1):68-72.
38. Arrive E, Viard JP, Salanave B, Dollfus C, Ma- theron S, Reliquet V, Arezes E, Nailler L, Vigou- roux C, Warszawski J; ANRS CO19 COVERTE and ENNS study groups. Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. PLoS One. 2018;13(11):e0206745
39. de Lima LRA, Back IC, Nunes EA, Silva DAS, Pe- troski EL. Aerobic fitness and physical activity are inversely associated with body fat, dyslipidemia and inflammatory mediators in children and adolescents living with HIV. J Sports Sci. 2019;37(1):50-58.
40. Zárate Sanabria, Andrés Gabriel et al. Intervención educativa sobre virus de inmunodeficiencia humana en la comunidad habitante de calle que asiste a un centro de acogida en la ciudad de Bogotá D.C. – Colombia. Nova, [S.l.], v. 15, n. 28, p. 11 - 17, oct. 2017. ISSN 2462-9448. Disponible en:
41. Del Amo J, Campbell C, Navarro G, Segura F, Suárez I, Teira R, et al. HIV in Spain 2017: policies for a new management of chronicity beyond viro- logical control]. Rev Esp Salud Publica. 2018 Sep 6;92. pii: e201809062.
42. Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, Wierzbicki AS. Pro-pro- tein subtilisin kexin-9 (PCSK9) inhibition in prac- tice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13032. Epub 2017 Oct 10
43. Ruscica M, Watts GF, Sirtori CR. PCSK9 in HIV infection: New opportunity or red herring? Atheros- clerosis. 2019;284:216-217
44. Nawej Tshikung O, Calmy A. [Antiretroviral treat- ments: towards simplified regimens? Rev Med Suis- se. 2018;14(588-589):102-106.
45. Hsu DC, O’Connell RJ. Progress in HIV vac- cine development. Hum Vaccin Immunother. 2017;13(5):1018-1030.
46. Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner N; NHLBI AIDS Blood Session Wor- king Group. NHLBI AIDS Blood Session Wor- king Group. Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood. 2013;122(18):3111-3115.
Descargas
La descarga de datos todavía no está disponible.
Horario: Lunes a Viernes: 8:00 a.m. a 5:00 p.m
